FLUICELL RECEIVES A NEW PATENT ACCEPTANCE FOR THE BIOPEN SYSTEM
Fluicell AB, a pioneering high-tech company in single-cell biology, is extremely delighted to announce the issuance of US Patent No 9,6719,671,366, entitled “Pipettes, methods of use, and methods of stimulating an object of interest”, by the USPTO. This is the third patent issued to Fluicell AB, representing a continued advancement of their innovative BioPen system. This platform facilitates complex cell biology experiments at the single-cell level, at affordable prices. This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell